Menopause hormone therapy is the best treatment we have for moderate to severe hot flushes and night sweats. It protects bone too. It is not a drug for preventing heart disease, dementia or other long-term illness. That is the verdict of the Women’s Health Initiative. It enrolled 161,808 US women and followed them for up to 20 years (Review).
One lesson matters more than the rest. Your age changes the answer, and so do the years since your last period.
What Menopause Hormone Therapy Is
Menopause hormone therapy means taking estrogen after your periods stop. Systemic estrogen travels through the whole body. It comes as a tablet, a skin patch or a gel. Doctors call hot flushes and night sweats vasomotor symptoms. Those are the symptoms the treatment is licensed to treat (Review).
If you still have a uterus, estrogen alone thickens its lining. That raises the risk of womb cancer. So doctors add a second hormone, a progestin, to protect it (Statement). Women who have had a hysterectomy take estrogen on its own. That one difference runs through the rest of this article.
Local vaginal estrogen is a separate treatment. It is a cream, tablet or ring for vaginal dryness and pain during sex. Very little of it reaches the rest of the body, so it does not carry the same warnings (Statement).
The problem it treats is not brief. Researchers followed 3,302 US women through menopause. Of those, 1,449 had frequent hot flushes or night sweats. For the typical woman they lasted about 7 years (Study). Women whose symptoms began before their periods stopped had them far longer, often past 11 years. Black women had the longest run, about 10 years. For white women it was about 6 and a half.
A separate US group followed 255 women and looked only at the worst symptoms. Moderate to severe hot flushes lasted about 4 and a half years on average after the final period. Some of these women were watched for 10 years or more. A third of them were still having hot flushes (Study).
What the 2002 Headline Missed
In July 2002 the researchers stopped half the trial early. That half was testing estrogen plus progestin in 16,608 women who still had a uterus. A coin flip had decided who got hormones and who got dummy pills. After about five years the harms crossed a line the team had set in advance (Trial).
Here is what the halt actually reported, counted per 10,000 women each year. There were 7 more heart events, 8 more strokes, 8 more lung clots and 8 more breast cancers. There were also 6 fewer bowel cancers and 5 fewer broken hips (Trial). Deaths from any cause were the same in both groups.
Those are small numbers, and the team reported them honestly. The headline was not small. It said hormones cause breast cancer and heart disease, with no numbers attached.
One detail did most of the damage. The average woman in that trial was 63 years old, and only a third were in their fifties (Trial). Roughly two thirds were at least 10 years past their last period. About a quarter were 20 years past it (Trial).
So the trial asked whether hormones prevent disease in older women. It did not ask whether they help a 52-year-old who cannot sleep. The answer to the first question got applied to everyone. Hormone headlines age badly in both directions, which is also the story of testosterone therapy in men.
Prescribing collapsed within a year. US hormone prescriptions had run at about 91 million a year in 2001. By 2003 they were on track for about 57 million (Study). Prescriptions for the estrogen-plus-progestin product fell by two thirds in twelve months.
Women stopped taking them and did not come back. In national surveys, 22 in every 100 US women over 40 were on these pills in 2001 and 2002. By 2003 and 2004 it was 12 in every 100 (Study). Among women in their fifties, use fell from about 33 in every 100 to 19. By 2009 and 2010 fewer than 5 in every 100 women over 40 still took them.
The Symptoms It Treats Best
A 2004 review pooled 24 trials in 3,329 women. Estrogen tablets cut hot flushes by about 18 a week more than dummy pills did (Meta-analysis). Women on dummy pills were far more likely to quit because nothing was happening.
That other group deserves a mention. Women on dummy pills improved too, by nearly 60% from where they started (Meta-analysis). Time and expectation both do real work in hot flush trials.
A modern trial shows the same shape in daily numbers. It gave 339 women low-dose estradiol, an antidepressant or dummy pills for 8 weeks. They started with about 8 hot flushes a day. Estradiol brought that down to about 4 a day, and dummy pills to about 5 and a half. Allowing for where each group started, the researchers put the drug’s own effect at about 2 fewer hot flushes a day (Trial).
Those 2 flushes a day are what the hormone itself adds, and that is a small but real gain. It looks bigger in a simple before-and-after number. In trials of a non-hormonal hot flush drug, dummy pills accounted for about four fifths of the improvement women felt (Meta-analysis).
Bone is the second solid answer. The estrogen-plus-progestin trial took ordinary women past menopause, not women picked for weak bones. Among those whose bone density was measured, fewer than 6 in every 100 had osteoporosis at the start. Broken bones of any kind hit 8.6% of the women on hormones and 11.1% of those on dummy pills (Trial). Hip fractures ran 52 against 73.
The protection showed up in every group the researchers looked at, including women whose bone density was normal (Trial). Across both hormone trials, hip fractures fell by about a third while women were taking the pills (Trial).
The benefit fades once you stop. Researchers tracked 15,187 women for 5 years after treatment ended. In the estrogen-plus-progestin group the fracture benefit had gone (Trial). In the estrogen-alone group a smaller benefit lingered. Nobody’s fracture rate climbed above the dummy-pill group’s, so there is no rebound to fear. Loading the skeleton is the other lever, which is part of why strength training earns its place in a longevity routine.
Not a Prevention Drug
The second finding has held up for two decades. The investigators state it plainly. These trials do not support hormone therapy for preventing heart disease or other chronic illness (Review).
Follow both hormone trials out 18 years and deaths come out level. About 27 in every 100 women had died in the hormone groups. In the dummy-pill groups it was about 28 in every 100 (Trial). Deaths from heart disease and from cancer matched too.
The trial also looked at memory. A smaller study inside it enrolled 4,532 women aged 65 and over. After about four years, 40 women on estrogen plus progestin had developed probable dementia. On dummy pills the count was 21 (Trial). That works out at about 23 extra cases per 10,000 women each year. The rate roughly doubled. The whole finding rests on 61 cases, though, so its true size is uncertain.
Those women were 65 to 79 when they started. Starting near menopause is a different question, and researchers have asked it. In one follow-up, women who began within three years of their last period were retested about a decade later. Their thinking scores matched those of the women given dummy pills (Study). Only about 4 in 10 of the original group came back, so read that as reassurance rather than proof.
A second trial tested memory in 567 women. Some were early after menopause and some were more than 10 years past it. Estradiol changed nothing in either group (Trial). The honest reading runs both ways. Hormone therapy is not a way to protect your brain, and starting it near menopause has not been shown to harm it.
Why Timing Changes the Answer
Age at the start moves the balance. The WHI review says the case for beginning before 60 rests on two things: better symptom relief, and fewer side effects than in later menopause (Review).
Pooled trial data point the same way. In trials of women who started under 60, deaths from any cause were lower than on dummy pills. In trials of women who started after 60, they were not (Meta-analysis). The heart disease signal leaned the same way. It was weaker, and it faded once the researchers dropped the trials where women knew what they were taking.
Two things should slow you down here. Stroke risk went up in both age groups, with no sign that starting early protects against it. And those groups came from each trial’s average starting age, not from each woman’s own years since menopause (Meta-analysis). The authors say so themselves.
The WHI’s own long follow-up is cautious. Women who started in their fifties did have slightly fewer deaths. Then the years after treatment were counted in. The pattern across age groups was small enough that chance could explain it (Trial).
Only one trial was built to test timing head on. ELITE gave 643 women estradiol or dummy pills. It split them by whether they were under 6 years or over 10 years past menopause. In the early group, the neck artery wall thickened more slowly. In the late group nothing changed (Trial). Scans of the heart’s own arteries, taken once at the end, showed no difference in either group.
So the timing idea has support, and it has limits. Artery wall thickness is a stand-in measurement, not a heart attack. Most of the rest comes from looking back at subgroups. No trial was designed to prove that starting early prevents disease.
Type and Route Both Matter
The 2002 headline treated hormone therapy as one thing. It is at least two.
Follow the WHI trials out to 20 years and they part company on breast cancer. Among 10,739 women taking estrogen alone after a hysterectomy, 238 developed breast cancer, against 296 on dummy pills. Fewer died of it too, 30 against 46 (Trial). Among 16,608 women on estrogen plus progestin, 584 developed breast cancer, against 447 on dummy pills. Deaths from breast cancer were 71 against 53, a gap small enough that chance could explain it.
The estrogen-alone result is not a WHI quirk. Pool all 10 trials of estrogen alone and 3.6 in every 100 women taking it developed breast cancer. On dummy pills it was 4.7 in every 100 (Meta-analysis). Most of that difference comes from the one large WHI trial, so treat it as one strong signal rather than ten.
The WHI investigators answered their critics in a single line. Estrogen alone lowers breast cancer in women who have had a hysterectomy. Estrogen plus progestin raises it, and that increase lasts two decades (Review). Large studies that simply watched women disagree, and make both forms look harmful. The trials are the better evidence here, because a coin flip decided who took what.
Route is the other difference the headline erased. A swallowed tablet passes through the liver first, which shifts the proteins that control clotting. A patch or gel does not. Pooling 15 studies that watched women’s own choices, tablets carried a higher risk of a first blood clot than patches did (Meta-analysis). A 2023 review of 51 studies calls clot risk the clearest difference between the two routes (Review).
That evidence is thinner than it sounds. A 2025 Canadian assessment looked at every study comparing clot risk between the routes. In all of them, no coin flip decided who used a tablet and who used a patch (Review). The studies also disagreed with each other. One large study found no difference between the routes at all. The people who pooled the data rate their own confidence as low (Meta-analysis).
There is one more recent development. In November 2025 the US regulator asked manufacturers to change these labels. The heart disease, breast cancer and dementia language came out of the boxed warning (Statement). The womb cancer box stays on systemic estrogen-alone products. The heart and breast cancer warnings moved elsewhere in the label rather than vanishing. The label also gained new wording about starting under 60, or within 10 years of menopause.
A label change is not new trial evidence. The regulator’s own account says the decision came from re-reading the WHI and later publications, plus an expert panel (Statement). In a November 2025 note, the WHI investigators said they take no position on the label. They added that no similarly large trial since theirs has changed the balance of risks and benefits for oral hormone therapy (Statement).
Frequently Asked Questions
Is Menopause Hormone Therapy Safe?
Safety depends on who you are. Menopause hormone therapy is considered reasonable for bothersome hot flushes in women under 60, or within 10 years of their last period (Review). That assumes there is no medical reason to avoid it. The known risks are real, but the extra numbers are small: more strokes, more blood clots and, with the combined form, more breast cancers (Trial). A history of breast cancer or of blood clots changes the sums, which is why this is a conversation, not a rule.
Does Hormone Therapy Cause Breast Cancer?
It depends which one. Over about 20 years of follow-up, estrogen plus progestin raised breast cancer cases, and the increase persisted. Estrogen alone, taken by women who had a hysterectomy, lowered both cases and deaths (Trial). Pooling every trial of estrogen alone points the same way (Meta-analysis). Studies that simply watched women taking hormones suggest both forms raise risk, so the two kinds of evidence do not agree (Review).
Is It Too Late to Start Hormone Therapy at 60?
Starting later tilts the balance the wrong way. In pooled trials, the survival and heart signals seen in younger starters are absent in women who begin after 60 (Meta-analysis). Dementia risk rose in women who started at 65 or older (Trial). That is not the same as a ban, and severe symptoms at 61 are still worth raising with a clinician.
What Happens When You Stop Hormone Therapy?
The bone protection fades. Five years after stopping, women who had taken estrogen plus progestin broke bones at the same rate as the dummy-pill group (Trial). No rebound appeared, and fracture rates did not overshoot. Hot flushes may return for some women, since the symptoms tend to run for years (Study).
Key Takeaways
- Symptom relief is the strong indication. Estrogen cuts hot flushes by about 18 a week more than dummy pills, roughly 2 fewer a day (Meta-analysis).
- Bone protection is real but temporary. Broken bones hit 8.6% of women on hormones against 11.1% on dummy pills, and the benefit faded after stopping (Trial).
- It is not a prevention drug. Over 18 years there was no survival benefit, and dementia rose in women who started at 65 or older (Trial).
- Timing shifts the balance. Under 60, or within 10 years of your last period, the trade looks better than it does later (Review).
- The two forms are different drugs. Estrogen alone and estrogen plus progestin moved breast cancer in opposite directions across 20 years (Trial).
Bring the Numbers to Your Doctor
None of this decides anything for you. The balance turns on four personal facts: your age, your years since your last period, your breast cancer history and your clot history. Only someone who knows all four can weigh them with you.
The main finding is unchanged since 2002. What we have now is far more detail. The trial reported small extra risks in women whose average age was 63. That got compressed into a single sentence about breast cancer and heart disease. Twenty years of follow-up have pulled that sentence apart into its pieces.
If hot flushes are wrecking your sleep, the numbers here are worth taking to an appointment. Ask which form is being proposed, by which route, and at what age you are starting. Those three questions cover most of what the evidence can actually tell apart.
A 24-year-old headline is a thin basis for a decision about your own body. The trial itself gives you far more to work with.
This article is for educational purposes and is not medical advice. Talk to a qualified clinician before changing your health regimen.
Leave a comment